Selected article for: "disease final stage and final stage"
Author: Aricò, Eleonora; Bracci, Laura; Castiello, Luciano; Gessani, Sandra; Belardelli, Filippo
Title: Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?
  • Cord-id: ur071q7h
  • Document date: 2020_7_4
    • ID: ur071q7h
    Snippet: Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) – mainly IFN-α and β –represent ideal candidates given their direct and immune-mediated antiviral effects and t
    Document: Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) – mainly IFN-α and β –represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic.

    Search related documents:
    Co phrase search for related documents
    • acquire immunity and local injection: 1
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and adaptive immune response: 1, 2, 3
    • action mechanism and adaptive immune response innate: 1
    • action mechanism and additive effect: 1, 2, 3, 4
    • action mechanism and administration dose: 1
    • action mechanism and long intensive: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and low dosage: 1
    • action mechanism and lung epithelial cell: 1, 2
    • action mechanism and lung infiltration: 1, 2
    • action mechanism and lung inflammatory cytokine: 1
    • action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active promote and acute respiratory syndrome: 1, 2